ArticleMetabolomics : Official journal of the Metabolomic Society2025
Untargeted metabolomic profiling of serum and urine in kidney cancer: a non-invasive approach for biomarker discovery.
Article in Metabolomics : Official journal of the Metabolomic Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Serum and urine metabolic fingerprints enable diagnosis and prognosis for IgA nephropathy.Materials today. Bio · 2025Article
- Metabolic reprogramming in clear cell renal cell carcinoma: core pathways and targeted therapeutic strategies.Frontiers in genetics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionKidney cancer (KC) is a significant global health burden. Early diagnosis remains challenging due to the limited sensitivity and specificity of existing biomarkers. Metabolomics enables the detection of disease-specific metabolic alterations, offering potential for improved non-invasive biomarker discovery.
objectivesThis study aims to characterize metabolic signatures distinguishing KC patients from non-cancer controls and evaluate the diagnostic potential of annotated metabolites in serum and urine.
methodsAn untargeted metabolomic analysis was performed on serum and urine samples from 56 KC patients and 200 controls using ultra-high-resolution mass spectrometry coupled with ultra-high-performance liquid chromatography (UHPLC-UHRMS in both positive and negative ionization modes with vacuum insulated probe heated electrospray ionization (VIP-HESI)). Samples were collected from the same individuals, which helped minimize inter-individual variability and enabled cross-biofluid comparison of metabolic profiles. Multivariate statistical techniques were applied to detect metabolic differences, including principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA). An external validation strategy using training and validation subsets was employed to assess the robustness of candidate metabolite biomarkers matched in the discovery dataset.
resultsDistinct metabolic signatures were observed between KC patients and controls, with key metabolic pathways involving lipid metabolism, amino acid biosynthesis, and glycerophospholipid metabolism. 19 serum and 12 urine metabolites showed high diagnostic potential (AUC > 0.90), demonstrating strong sensitivity and specificity.
conclusionThese findings support the application of metabolomics for RCC detection and highlight the metabolic alterations associated with kidney cancer. Further validation in larger cohorts is necessary to confirm the clinical utility of these potential biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.